Tilray Shares Experience Historic Swings Following Trump’s CBD Endorsement

Tilray’s stock demonstrated extraordinary market volatility this week, recording one of the most significant single-day movements in recent cannabis sector history. The catalyst emerged from an unexpected source: former President Donald Trump’s public endorsement of CBD products, which triggered a dramatic 61% surge in the company’s share price within just twenty-four hours.

Political Announcement Fuels Speculative Frenzy

The rally ignited when Trump released a nearly three-minute video on Truth Social, where he characterized CBD as “revolutionary for senior healthcare.” This political endorsement immediately translated into massive buying pressure, driving Tilray’s stock price to $1.85 and establishing new 52-week highs.

Market Response Metrics:
– Trading volume exploded to 371.5 million shares
– Cannabis-focused ETFs followed with gains exceeding 20%
– Options market data suggests continued volatility ahead

This political development carries substantial implications for the entire cannabis industry, particularly regarding potential marijuana reclassification at the federal level.

Volatility Continues with Sharp Pullback

The euphoria proved short-lived as Tilray shares retreated 6.5% the following day, settling at $1.73. This swift correction highlights the extreme price fluctuations characteristic of cannabis investments tied to regulatory speculation.

These violent price swings reflect investor uncertainty about both the timing and scope of potential U.S. cannabis policy reforms. Current options pricing indicates implied movements exceeding 23% through the coming weekend.

Regulatory Reform Potential

Marijuana currently maintains its Schedule I substance designation under federal law, creating significant operational constraints for cannabis companies. A potential rescheduling would eliminate Section 280E tax burdens, which currently prohibit standard business deductions.

Should investors sell immediately? Or is it worth buying Tilray?

A regulatory shift could fundamentally transform Tilray’s business model through multiple channels:
– Establishment of traditional banking relationships
– Substantial reduction of tax liabilities
– Enhanced access to capital markets
– Facilitated entry of institutional investors

Financial Performance Overview

Tilray’s fiscal year 2025 results showed net revenue reaching $821.3 million, representing 4% year-over-year growth. The company reported gross profit of $240.6 million with margins holding at 29%.

The company continues to successfully diversify its revenue streams. Beverage sales generated $241 million, nearly matching cannabis revenue of $249 million. This strategic positioning establishes Tilray as the fourth-largest craft beer producer in the United States.

Upcoming Catalysts

Market attention now turns to October 9, when Tilray is scheduled to report first-quarter fiscal 2026 results. Financial analysts project a loss per share of -$0.03, which would represent a 25% year-over-year improvement.

Revenue expectations stand at $206.83 million, equating to growth of 3.39% if achieved. These quarterly figures will provide crucial insights into the company’s operational performance and strategic direction.

The central question remains whether Tilray can convert regulatory optimism into sustainable financial performance. Initial answers may emerge as early as next week.